Pharmacological Management of No Reflow during Percutaneous Coronary Intervention

Current Vascular Pharmacology

Volumn 4, Issue 2, 2006, Pages 95-100

  Porto, Italo ^a   Ashar, Vaishali ^a   Mitchell, Andrew R J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Glycoprotein IIbIIIa antagonist; Myocardial infarction; No reflow; Percutaneous coronary intervention; Vasodilator

Indexed keywords

ABCIXIMAB; ADENOSINE; ADRENALIN; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; NICARDIPINE; NICORANDIL; NITRATE; NITROPRUSSIDE SODIUM; PAPAVERINE; VASOCONSTRICTOR AGENT; VERAPAMIL; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; ANGIOGRAPHY; BLOOD FLOW; HUMAN; INCIDENCE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SAPHENOUS VEIN GRAFT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG EFFECT; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY CIRCULATION; CORONARY DISEASE; HUMANS; POSTOPERATIVE COMPLICATIONS;

EID: 33646039822     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106776359835     Document Type: Review

References (66)

1. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101(2): 125-30.
2. Kloner RA, Ganote CE, Jennings RB. The 'no-reflow' phenomenon following temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-1508.
3. Bates ER, Krell MJ, Dean EN, O'Neill WW, Vogel RA. Demonstration of the "no-reflow" phenomenon by digital coronary arteriography. Am J Cardiol 1986; 57: 177-8.
4. Schoffer J, Montz R, Mathey D. Scintigraphic evidence of the 'no-reflow' phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol 1985; 5: 593-8.
5. Pomerantz RM, Kuntz RE, Diver DJ, Safian RD, Baim DS. Intracoronary verapamil for the treatment of distal microvascular coronary artery spasm following PTCA. Cathet Cardiovasc Diagn 1991; 24: 283-5.
6. Wilson RF, Lesser JR, Laxson DD, White SW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesion. Lancet 1989; 1: 807-11.
7. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-8.
8. Feld H, Schulhoff N, Lichstein E, Greengart A, Frankel R, Shani J. Direct angioplasty as primary treatment for acute myocardial infarction resulting in the "no-reflow" phenomenon predicts a high mortality rate. Circulation 1992; 86(supp lI): I135 Abstract.
9. Yip HK, Chen MC, Chang HW, Hang CL, Hsieh YK, Fang CY, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 2002; 122: 1322-32.
10. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130: 239-43.
11. Cura FA, L'Allier PL, Kapadia SR, Houghtaling PL, Dipaola LM, Ellis SG, et al. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol 2001; 88: 124-8.
12. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42-6.
13. Sellke FW, Myers PR, Bates JN, Harrison DG. Influence of vessel size on the sensitivity of porcine microvessels to nitroglycerine. Am J Physiol 1990; 258: H515-20.
14. Lamping KG, Kanatsuka H, Eastham CL, Chilian WM, Marcus ML. Non-uniform vasomotor responses of the coronary microcirculation to serotonin and vasopressin. Circ Res 1989; 65: 343-51.
15. Quillen JE, Harrison DG. Vasomotor properties of porcine endocardial and epicardial microvessels. Am J Physiol 1992; 262: H1143-8.
16. Pelc LR, Garrett GJ, Warltier DC. Preferential increase in subendocardial perfusion produced by endothelium - dependent vasodilators. Circulation 1987; 76: 191-200.
17. Quillen JE, Sellke FW, Brooks LA, Harrison DG. Ischemia - reperfusion impairs endothelium-dependent relaxations of coronary microvessels but does not affect large vessels. Circulation 1990; 82: 586-94.
18. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction in clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
19. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001; 103: 2550-4.
20. The CAPTURE investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
21. The PRISM-PLUS investigators. The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS). N Engl J Med 1998; 338: 1488-97.
22. Neumann F-J, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effects of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-2701.
23. Coller BS. GpIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997; 78: 730-5.
24. Kaul U, Sapra R, Singh B, Sudan D, Ghose T, Dixit NS, et al. Reversal of slow flow phenomenon during primary stenting by bail-out administration of abciximab. Int J Cardiovasc Intervent 2000; 3(1): 35-9.
25. Collet JP, Montalescot G, Lesty C, Mishal Z, Soria J, Choussat R, et al. Effect of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001; 103: 2328-31.
26. Wohrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003; 107(14): 1840-3.
27. Burzotta F, Romagnoli E, Trani C, Crea F. Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circulation 2003; 108(19): e138.
28. Pakala R. Serotonin and thromboxane A2 stimulate platelet-derived microparticle induced smooth muscle cell proliferation. Cardiovasc Radiat Med 2004; 5(1): 20-6.
29. Hara K, Hirowatari Y, Yoshika M, Komiyama Y, Tsuka Y, Takahashi H. The ratio of plasma to whole blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. J Lab Clin Med 2004; 144(1): 31-7.
30. Naimushin YA, Mazurov AV. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules. Biochemistry (Mosc) 2003; 68(2): 209-16.
31. Mathew V, Grill DE, Scott CG, Grantham A, Ting HH, Garratt KN, et al. The influence of Abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol 1999; 34: 1163-9.
32. Williams MS, Coller BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab. Circulation 1998; 98: 742-8.
33. Rawitscher D, Levin TN, Cohen I, Feldman T. rapid reversal of no-reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997; 42: 187-90.
34. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, et al. Am Heart J 2004; 147(3): 457-62.
35. Rubanyi G, Vanhoutte PM. Endothelium removal decreases relaxation of canine coronary arteries caused by b-adrenergic agonists and adenosine. J Cardiovasc Pharmacol 1985; 7: 139-44.
36. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschorn R. Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 47: 760-70.
37. Cronstein BN, Kramer SB, Weissmann G, Hirschorn R. Adenosine: a physiologic modulator of superoxide generation by human neutrophils. J Exp Med 1983; 158: 1160-77.
38. Brown JY, Lassley RD, Ely SW, Berne RM, Mentzer Jr RM. Augmentation of endogenous adenosine improves post-ischaemic ventricular function. Eur J Physiol 1986; 407(suppl I): 121.
39. Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987; 76(6): 1135-45.
40. Gessi S, Varani K, Merighi S, Ongini E, Borea PA. A2A adenosine receptors in human peripheral blood cells. Br J Pharmacol 2000; 129(1): 2-11.
41. Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, Anfossi G. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Thromb Res 2004; 114(4): 265-73.
42. Assali AR, Sdringola S, Ghani M, Denktas A, Yepes A, Hanna GP, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of no-reflow phenomenon. Catheter Cardiovasc Interv 2000; 51: 27-31.
43. Fischell TA, Carter AJ, Foster MT, Hempsall K, DeVries J, Kim Dennis, et al. Reversal of no-reflow during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998; 45: 360-5.
44. Sdringola S, Assali A, Ghani M, Yepes A, Rosales O, Schroth GW, et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no-reflow phenomenon. Catheter Cardiovasc Interv 2000; 51: 394-9.
45. Parham WA, Bouhasin A, Ciaramita JP, Khoukaz S, Herrmann SC, Kern MJ. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 2004; 109(10): 1236-43.
46. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2004; 63(2): 171-6.
47. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37(5): 1335-43.
48. Barcin C, Denktas AE, Lennon RJ, Hammes L, Higano ST, Holmes DR Jr, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004; 61(4): 484-91.
49. Miura T, Miki T. ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart. Curr Vasc Pharmacol 2003; 1: 251-8.
50. Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J 2004; 148(4): E15.
51. Tsubokawa A, Ueda K, Sakamoto H, Iwase T, Tamaki S. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circ J 2002; 66(12): 1119-23.
52. Lim SY, Bae EH, Jeong MH, Kang DG, Lee YS, Kim KH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J 2004; 68(10): 928-32.
53. Fischell TA, Maheshwari A. Current applications for nicardipine in invasive and interventional cardiology. J Invasive Cardiol 2004; 16(8): 428-32.
54. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000; 12(2): 80-85.
55. Pomerantz RM, Kuntz RE, Diver DJ, Safian RD, Baim DS. Intracoronary verapamil for the treatment of distal microvascular coronary artery spasm following PTCA. Cathet Cardiovasc Diagn 1991; 24: 283-5.
56. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, et al. Treatment of no reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet and Cardiovasc Diagn 1996; 39: 113-8.
57. Campbell CA, Kloner RA, Alker KJ, Braunwald E. Effect of verapamil on infarct size in dogs subjected to coronary artery occlusion with transient reperfusion. J Am Coll Cardiol 1986; 8: 1169-74.
58. Oldenburg O, Eggebrecht H, Herrmann J, Naber CK, Haude M, Erbel R, et al. Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. Cardiovasc Drugs Ther 2000; 14(6): 651-5.
59. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002; 57(4): 444-51.
60. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 2002; 14(6): 299-302.
61. Ishihara M, Sato H, Tateishi H, Kawagoe T, Yoshimura M, Muraoka Y. Impaired coronary flow reserve immediately after coronary angioplasty in patients with acute myocardial infarction. Br Heart J 1993; 73: 444-51.
62. Hellstrom HR. The injury-spasm (ischemia-induced hemostatic vasoconstrictive) and vascular autoregulatory pothesis of ischemic disease; resistance vessels-spasm hypothesis of ischemic disease. Am J Cardiol 1982; 49: 802-10.
63. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132: 959-63.
64. Kloner RA, Alker K, Campbell C, Figures G, Eisenhauer A, Hale S. Does tissue-type plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi? Circulation 1989; 79: 1125-36.
65. Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no reflow phenomenon during coronary reperfusion. Circulation 1984; 70: 513-21.
66. Matsumoto H, Inoue N, Takaoka H, Hata K, Shinke T, Yoshikawa R, et al. Depletion of antioxidants is associated with no-reflow phenomenon in acute myocardial infarction. Clin Cardiol 2004; 27(8): 466-70.